Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company that develops and commercializes medical products based on its proprietary rhCollagen™ technology, a recombinant human collagen produced using genetically modified tobacco plants. The company operates primarily in the biotechnology and medical aesthetics industries, focusing on applications where collagen is a critical structural or functional component.
The company’s core revenue drivers include commercial sales of dermal fillers, licensing and collaboration agreements, and research and development partnerships. CollPlant serves customers in the medical aesthetics, regenerative medicine, and medical device markets, targeting both clinicians and strategic industry partners. Founded in 2004 in Israel, the company initially focused on plant-based protein expression and later evolved into a collagen-focused biotechnology platform company following advancements in recombinant human collagen manufacturing.
Business Operations
CollPlant’s operations are centered around the development, manufacturing, and commercialization of products derived from rhCollagen™, which is designed to be bio-identical to human collagen and free of animal-derived components. The company generates revenue through product sales, milestone payments, licensing fees, and collaborative research funding. Its commercial-stage product portfolio includes dermal fillers marketed in select international markets, while additional product candidates remain in clinical or preclinical development.
Operations span both domestic and international activities, with research, development, and manufacturing primarily conducted in Israel, and commercialization and partnerships extending into North America, Europe, and Asia. CollPlant controls proprietary manufacturing processes, formulation technologies, and intellectual property related to plant-based recombinant collagen. The company has entered into strategic collaborations with global medical device and aesthetics companies to co-develop and commercialize products based on its technology platform.
Strategic Position & Investments
CollPlant’s strategic direction emphasizes leveraging its rhCollagen™ platform through partnerships rather than building a large direct commercial infrastructure. Growth initiatives focus on expanding applications of recombinant human collagen in medical aesthetics, tissue regeneration, and implantable medical devices. The company has pursued selective investments in research programs aimed at next-generation dermal fillers, soft tissue repair, and regenerative scaffolds.
Key strategic activities include licensing agreements and joint development collaborations with established industry players, which provide non-dilutive funding and access to global distribution networks. CollPlant continues to invest in emerging applications of recombinant collagen where safety, consistency, and scalability provide a competitive advantage over animal-derived collagen alternatives. Data inconclusive based on available public sources regarding material equity investments in external portfolio companies.
Geographic Footprint
CollPlant is headquartered in Rehovot, Israel, which serves as the central hub for research, development, and manufacturing. The company maintains a global market presence through distributors, partners, and collaborators across North America, Europe, and parts of Asia.
While the majority of operational assets are based in Israel, the company’s commercial reach is international, with regulatory approvals and product sales in multiple countries. Strategic collaborations with multinational partners extend CollPlant’s influence into major global healthcare and aesthetics markets without the need for extensive physical infrastructure outside its home region.
Leadership & Governance
CollPlant is led by an executive team with experience in biotechnology, medical devices, and life sciences commercialization. The leadership emphasizes a strategy focused on intellectual property development, disciplined capital allocation, and partnership-driven growth to maximize the value of its collagen platform.
Key executives include:
- Yehiel Tal – Chief Executive Officer
- Yakir Barchana – Chief Financial Officer
- Dr. Eyal Netz – Chief Technology Officer
- Dr. Sagi Ben-Yehuda – Vice President, Research & Development
The company operates under a governance framework aligned with U.S. public company standards, as it is listed on Nasdaq, and maintains board oversight consistent with regulatory and investor expectations.